Integrated human organ-on-a-chip model for predictive studies of anti-tumor drug efficacy and cardiac safety.

ABSTRACT: Traditional drug screening models are often unable to faithfully recapitulate human physiology in health and disease, motivating the development of microfluidic organs-on-a-chip (OOC) platforms that can mimic many aspects of human physiology and in the process alleviate many of the discrepancies between preclinical studies and clinical trials outcomes. Linsitinib, a novel anti-cancer drug, showed promising results in pre-clinical models of Ewing Sarcoma (ES), where it suppressed tumor growth. However, a Phase II clinical trial in several European centers with patients showed relapsed and/or refractory ES. We report an integrated, open setting, imaging and sampling accessible, polysulfone-based platform, featuring minimal hydrophobic compound binding. Two bioengineered human tissues - bone

SUBMITTER: Chramiec A 

PROVIDER: S-EPMC8092329 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature